- Home
- MOS vs NUVL Comparison
MOS vs NUVL Comparison
Compare MOS & NUVL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MOS
- NUVL
- Stock Information
- Founded
- MOS 2004
- NUVL 2017
- Country
- MOS United States
- NUVL United States
- Employees
- MOS N/A
- NUVL N/A
- Industry
- MOS Agricultural Chemicals
- NUVL Biotechnology: Pharmaceutical Preparations
- Sector
- MOS Industrials
- NUVL Health Care
- Exchange
- MOS Nasdaq
- NUVL Nasdaq
- Market Cap
- MOS 8.1B
- NUVL 6.7B
- IPO Year
- MOS 2004
- NUVL 2021
- Fundamental
- Price
- MOS $23.70
- NUVL $80.59
- Analyst Decision
- MOS Hold
- NUVL Strong Buy
- Analyst Count
- MOS 11
- NUVL 10
- Target Price
- MOS $32.22
- NUVL $112.60
- AVG Volume (30 Days)
- MOS 4.4M
- NUVL 411.4K
- Earning Date
- MOS 02-19-2025
- NUVL 02-25-2025
- Dividend Yield
- MOS 3.49%
- NUVL N/A
- EPS Growth
- MOS N/A
- NUVL N/A
- EPS
- MOS 1.15
- NUVL N/A
- Revenue
- MOS $11,456,400,000.00
- NUVL N/A
- Revenue This Year
- MOS N/A
- NUVL N/A
- Revenue Next Year
- MOS $5.07
- NUVL N/A
- P/E Ratio
- MOS $20.93
- NUVL N/A
- Revenue Growth
- MOS N/A
- NUVL N/A
- 52 Week Low
- MOS $23.60
- NUVL $61.80
- 52 Week High
- MOS $37.30
- NUVL $113.51
- Technical
- Relative Strength Index (RSI)
- MOS 37.74
- NUVL 27.16
- Support Level
- MOS $23.60
- NUVL $81.11
- Resistance Level
- MOS $24.39
- NUVL $84.83
- Average True Range (ATR)
- MOS 0.74
- NUVL 3.16
- MACD
- MOS -0.17
- NUVL -0.83
- Stochastic Oscillator
- MOS 15.54
- NUVL 2.31
About MOS Mosaic Company (The)
Formed in 2004 by the combination of IMC Global and Cargill's fertilizer business, Mosaic is one of the largest phosphate and potash producers in the world. The company's assets include phosphate rock mines in Florida, Brazil, and Peru and potash mines in Saskatchewan, New Mexico, and Brazil. Mosaic also runs a large fertilizer distribution operation in Brazil through its Mosaic Fertilizantes business, which the company acquired from Vale in 2018.
About NUVL Nuvalent Inc.
Nuvalent Inc is a clinical stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. All of the Company's operations are in the United States. The company is engaged in developing small molecules that are designed to overcome the limitations of existing therapies for clinically proven kinase targets. The product candidates of the company include NVL-520, which is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC), NVL-655, which is being developed for patients with anaplastic lymphoma kinase (ALK)-positive NSCLC, NVL-330, is a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to address the combined medical need of treating tumors driven by HER2ex20.